If we focus only on placement, we will continue to see cycles of progress and regression. If we focus on stability — on what happens after the keys are handed over — we have an opportunity to change those trajectories more permanently. The post Medicaid’s Housing Problem Isn’t Placement — It’s What Happens Next appeared…
Self-service patient access is a growing trend that’s here to stay. Tech-savvy patients want to see their doctor faster and don’t want to jump through complicated hoops to schedule an appointment, complete their registration paperwork or pay their medical bills. Opening the digital front door must be a priority for providers who want to keep…
This brief explores substance use and suicide deaths, finding that, collectively, these deaths ranked #3 in leading causes of death in the U.S. in 2024. Trends in substance use and suicide deaths over time and by demographics are also presented.
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring. The post Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec appeared first on MedCity News.
A just-released report from SullivanCotter sees salaries and incentive pay creeping up
GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year. The post GSK Inflammation Drug Lands New FDA Nod…
Doug Dietzman previously led interoperability strategy, policy and regulatory engagement at the Blue Cross Blue Shield Association
Mass General Brigham evaluates AI tools by carefully monitoring real-world performance before scaling them system-wide. At HIMSS earlier this month, Rebecca Mishuris, the health system’s chief health information officer and vice president of digital, explained what this process looks like. The post How Mass General Brigham Decides Which AI Tools Are Worth Scaling appeared first…
That is the question that a paper by Wong et al. (2024) aims to answer. FDA use the accelerated approval (AA) pathway to expedite the availability of drugs for serious or life-threatening conditions when a drug demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical…
[Sponsored] Facing a loss of patients and revenue to outside referrals, Hancock Health joined the Mayo Clinic Care Network and achieved a dramatic turnaround. The post Hancock Health’s $1.1M Turnaround appeared first on MedCity News.